A new way to screen for more cancers

The Galleri® multi-cancer early detection test detects a cancer signal across more than 50 types of cancer.1,2 It’s now available to employees enrolled in a Premier Medical Plan and their spouse or domestic partner who meet eligibility requirements.

Check Eligibility

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. Galleri should be used in addition to healthcare provider recommended screening tests.

Roger testimonial

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. Galleri should be used in addition to healthcare provider recommended screening tests.

Key benefits of the Galleri test

hourglass icon

Early cancer detection

Detects many cancers not commonly screened for today, to allow for earlier treatment.1

stethoscope icon

Testing with ease

Completed with a simple blood draw.

blue test result icon

Actionable results

If a cancer signal is found, the results can point to where in the body the cancer is coming from with high accuracy.

The Galleri test is a screening test and does not detect all cancers.
Further testing is needed to diagnose cancer if a signal is detected.

What is the Galleri test?

What is Galleri?

illustrated video poster of the Galleri test sitting on a table in an examination room with an anatomy poster on the wall behind it

Patient testimonial: Valerie

Who is eligible?

The Galleri test is offered as a covered benefit to eligible U.S. based Qualcomm employees and their spouse/domestic partner. This test is available to individuals aged 50 and older, or aged 35 - 49 with certain risk factors, and enrolled in a a Premier Medical Plan. Galleri is an annual benefit.

Eligibility criteria:

  • Employees and their spouse/domestic partner
  • 50 years old and older
  • 35 - 49 with risk factors
  • Enrolled a Premier Medical Plan
Black couple sitting at their kitchen table writing on a notepad with a cup of coffee and a tablet on the table in front of them

Galleri for Qualcomm

Galleri testing is available to eligible individuals through primary care providers at all Scripps Clinic and Scripps Coastal locations, and at the San Diego Qualcomm Health Centers.

You can request testing during your annual preventive visit. If you recently completed your annual preventive care visit, a separate appointment (virtual or in-person) must be scheduled to discuss and verify eligibility for the testing.

Please contact the Premier Plan Concierge at 844-884-7266 if you have questions or for help scheduling your visit.

Frequently Asked Questions

The Galleri test is offered as a covered benefit to eligible U.S. based Qualcomm employees and their spouse/domestic partner. This test is available to individuals aged 50 and older, or aged 35 - 49 with certain risk factors, and enrolled in a a Premier Medical Plan. Galleri is an annual benefit.

Eligibility criteria:

  • Employees and their spouse/domestic partner
  • 50 years old and older
  • Enrolled a Premier Medical Plan years or older
  • 35-49+ years old AND with one of the following:
    • Cancer survivor who has completed treatment at least 3 years ago*
    • Currently smokes or quit smoking less than 10 years ago
    • Diagnosis of cirrhosis or chronic Hepatitis B or C infection
    • Infection with certain strains of HPV (e.g. HPV 16 or 18)
    • Known hereditary cancer syndrome
      • Confirmation or documentation of a gene mutation associated with increased cancer risk (e.g., Li-Fraumeni syndrome, Hereditary Breast and Ovarian Cancer syndrome [BRCA1/2], Lynch syndrome, CHEK2).

        OR
  • 35-49+ years old AND with at least two of the following:
    • Documented genetic predisposition (germline variant)
    • First degree relative with cancer**
    • History of HIV infection
    • Current use of immunosuppressive therapies after organ transplantation
    • Diabetes
    • BMI
      • Male ≥ 35
      • Female ≥ 30

Use of Galleri is not recommended in individuals who are pregnant or undergoing active cancer treatment.

Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Additionally, those who do not meet the eligibility criteria as stated by Qualcomm will not be covered by the benefit.

If you meet the eligibility criteria established by Qualcomm in partnership with GRAIL (see "Who is eligible" question above), the full cost of the Galleri test is covered.

Other family members or friends not eligible through the Qualcomm benefit may learn more about the test on galleri.com. Those not eligible would be responsible for the cost of the test and PWNHealth provider services.

Note: only the member requesting a Galleri test kit can take the test.

Qualcomm employees and their spouse/domestic partner enrolled in a Premier Medical Plan who are aged 50 years or older or age 35-49 with specific risk factors, and their primary care provider is an authorized prescriber based on our phased roll-out are eligible. View eligibility criteria mentioned above.

As part of this benefit offering, eligible employees and their eligible dependents are limited to one Galleri test per calendar year.

The Galleri test is a multi-cancer early detection test that detects a cancer signal across more than 50 types of cancer, many of which are not commonly screened for today, through a simple blood draw. The Galleri test does not diagnose cancer and not all cancers may be detected in the blood.

The Galleri test is intended to be used in addition to, and not replace, other cancer screening tests your healthcare provider recommends.

The Galleri test looks for signals present in the blood that may be associated with cancer at the time of your blood draw. If a cancer signal is detected, the results can point to where in the body the cancer signal is coming from with high accuracy to help your healthcare provider guide next steps.

Family history is only one of many risk factors associated with cancer development. Other risk factors include eating habits, lifestyle, living or working environments, genetics, and many others.

Please discuss with your primary care physician during your visit to request the Galleri test.

In a clinical validation study (CCGA3*), the Galleri test detected more than 50 types of cancer across all stages.

*Circulating Cell-Free Genome Atlas (CCGA) sub-study

The Galleri test detects a cancer signal across more than 50 types of cancers; however, not all cancers may be detected in the blood. Recommended routine cancer screening tests such as colonoscopy or mammograms have been shown to reduce cancer deaths.

The Galleri test is intended to be used in addition to and not replace these tests, and can help maximize the benefits of early cancer detection. Missing recommended screening or ignoring symptoms could lead to a delayed diagnosis of cancer.

Based on data from our studies, the Galleri test has shown a low false-positive rate of 0.5% (detects a cancer signal when no cancer is present). This means that in approximately 200 people tested only 1 person would be expected to receive a false positive result.

Someone who has previously had cancer can take the Galleri test as long as they completed treatment at least 3 years ago and are in remission. If you’ve had cancer in the past, we recommend talking with your doctor to determine if Galleri is right for you.

In the event that a diagnostic evaluation after a “cancer signal detected” result with Galleri does not confirm cancer, employees may be eligible for a complementary re-test with Galleri.

The request for a re-test must be placed by the healthcare provider managing the employee's diagnostic evaluation. The re-test must be administered within 3-6 months after the initial Galleri test. To initiate a request for a re-test, the healthcare provider managing the employee's diagnostic evaluation should contact GRAIL Customer Service at 833-MY-GALLERI (833-694-2553) or customerservice@grail.com. Customer Service hours are Monday through Friday 5:00 AM - 5:00 PM PT.

The Galleri test development was supported by what is believed to be one of the largest clinical study programs in genomic medicine, with over 20,000 participants at more than 140 clinical study sites, including the Mayo Clinic, Dana-Farber Cancer Institute, Cleveland Clinic, Sutter Health, OHSU, Intermountain Healthcare, and U.S. Oncology Network. Please visit the Galleri clinical evidence page for more information.

The Galleri test has not been cleared or approved by the FDA. GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing.

The Galleri test received FDA Breakthrough Device Designation in 2019.

Once you have picked up the kit from your personal/primary care physician, you can go to any Scripps lab to have the blood draw done.

Bring your unopened Galleri sample collection kit and your completed Test Requisition Form to your blood draw.

(Appointment not required for blood draw.)

The Test Requisition Form is the ordering form the Scripps provider completes to order the test for you.

You will receive this document during your in-person visit with your provider. If you had a telehealth visit with your provider, you will need to pick up your Test Requisition Form from your provider’s office.

You will need to bring your Test Requisition Form and your sample collection kit to your blood draw.

No preparation or fasting is required.

Some lab technicians may ask if you have fasted (no eating or drinking), but this is not required for the Galleri test.

Please do not break the quality seal on the collection kit. It should be opened by the lab technician who draws your blood sample.

Store the collection kit at room temperature until your blood draw appointment. The contents are sensitive to extreme temperatures. For example, avoid storing your collection kit in the trunk of your car.

You can go to any Scripps lab for your blood draw. Note that an appointment at the lab in not required.

The lab technician who draws your blood will pack and ship your sample back to GRAIL for processing.

Approximately 1.5 tablespoons (or about 20 mL) of blood in two tubes typically from a vein in your arm.

Please contact GRAIL Customer Service at customerservice@grail.com or 833−694−2553 to let them know you will not be completing the test and discard of the kit.

Once you visit the lab for your blood draw, it can take 3-4 weeks for results to come back.

Negative results will be supplied by Grail and Scripps.

Positive results will be communicated through your personal/primary care physician.

If you no longer wish to receive your Galleri results, please contact PWNHealth to request a cancellation at gc@pwnhealth.com or 888-494-7333.

If you are unable to reach PWNHealth or require further assistance, please contact GRAIL Customer Service at customerservice@grail.com or 833−694−2553.

This means that no cancer signal was found. However, not all cancers can be detected by the Galleri test. Continue with all routine screening tests that your healthcare provider recommends. Missing routine screenings or ignoring symptoms can lead to a delayed diagnosis of cancer.

If you wish to discuss your result, you can reach out to your personal/primary health care physician.

This means that there is a suspicion of cancer, and additional tests are needed to see if you have cancer. Your personal/primary care provider who ordered your test will share this result with you and what it may mean.

The Galleri test can point to where in the body the cancer is coming from to help your primary healthcare provider guide next steps. Your primary healthcare provider will order appropriate follow-up testing to determine if cancer is present.

Galleri is a screening test that detects cancer signals in blood. When a signal is detected, the Galleri test also indicates where in the body the signal is coming from with high accuracy.

The Galleri test is not a diagnostic test. Additional tests ordered by your primary healthcare provider are needed to confirm if cancer is present which may include blood work or imaging.

In the event that a diagnostic evaluation after a “cancer signal detected” result with Galleri does not confirm cancer, employees may be eligible for a complementary re-test with Galleri.

The request for a re-test must be placed by the healthcare provider managing the employee's diagnostic evaluation. The re-test must be administered within 3-6 months after the initial Galleri test. To initiate a request for a re-test, the healthcare provider managing the employee's diagnostic evaluation should contact GRAIL Customer Service at 833-MY-GALLERI (833-694-2553) or customerservice@grail.com. Customer Service hours are Monday through Friday 5:00 AM - 5:00 PM PT.

The Galleri test is looking for the presence of cancer at the time your blood is drawn, but you may develop cancer in the future. The test does not measure your risk of developing cancer in the future and it does not detect all cancers.

Your primary healthcare provider (or personal / primary care physician) that orders the test will receive your test result and share it with you. Your test result and medical information are confidential and access is limited to individuals who need the information for a specific purpose.

Your employer only receives de-identified and aggregated information across all employees and will not receive individual results.

If you receive a “Cancer Signal Detected” result from the Galleri test, and follow-up diagnostic testing confirms a cancer diagnosis, it will not impact your other insurance products, like life insurance, through Qualcomm.

Existing cancer or cancer that is in remission would need to be disclosed in most insurance applications. This does not necessarily mean that new policy applications would be declined or require higher premiums.

Get support

For questions about the Galleri test, please contact GRAIL Customer Service:

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of ​“No Cancer Signal Detected” does not rule out cancer. A test result of ​“Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

  1. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77. DOI:https://doi.org/10.1016/j.annonc.2021.05.806.

  2. The Galleri test does not detect all cancers nor does it measure your genetic risk of developing cancer in the future. It should be used in addition to routine screening tests your healthcare provider recommends.